The FDA states that GLP-1 medications for weight management should only be used in conjunction with behavior modification, and now the WeightWatchers GLP-1 Program will be that complementary tool to provide the necessary behavioral support
The results were based on data received from U.S
The results of the trial were published in The Lancet on May 2, 2026
Sarcopenia and sarcopenic obesity and mortality among older people
1,2 Any decision about weight-loss injections for someone under 18 should involve a specialist obesity service and the young persons parents or guardians
When to seek medical advice: Patients taking GLP-1 medications should contact their GP or prescribing clinician if they experience persistent nausea affecting nutritional intake, signs of hypoglycaemia (if taking alongside other diabetes medications), severe abdominal pain (especially if radiating to the back, which may indicate pancreatitis), or any concerns about their response to treatment